Biotech called the shots in the Bay Area’s year-end capital scramble, with the single largest sale in the region clocking in at roughly $4 billion in biotech stock. Drug developers also drove a late-December wave of equity offerings, a mix of follow-on and secondary sales that signaled investors were again ready to write hefty checks for clinical-stage companies. Among the deals that closed just before New Year’s was an upsized underwritten offering from a Peninsula clinical-stage firm that pulled in hundreds of millions for development.
As reported by the San Francisco Business Times, secondary offerings announced by drug developers made up more than 60% of the stock sales disclosed by all Bay Area public companies in the fourth quarter. The Business Journals' roundup, written by Ron Leuty, highlighted the roughly $4 billion transaction as the biggest end-of-year sale in the region. Taken together, those numbers show just how much of the Bay Area’s fourth-quarter equity supply came from life-sciences players tapping the markets rather than from the usual tech suspects.
Big Raises, Focused Use Of Cash
Terns Pharmaceuticals priced an upsized public offering of 16,250,000 shares at $40 per share for gross proceeds of $650 million, and the company estimated net proceeds of roughly $705.8 million if the underwriters exercised their full option, according to the company’s SEC filing. The deal was marketed by Jefferies, TD Cowen and Leerink Partners and was expected to close on December 11. Terns said it plans to deploy the cash into research, clinical trials and manufacturing steps for its lead candidates. That single transaction helped make the final days of 2025 unusually busy for Bay Area biotechs heading back to the public markets.
Deals, M&A And A Thawing Market
Observers say the late-year action reflected broader market dynamics, with a handful of sizable deals and fresh data readouts nudging investor sentiment just enough to open the equity window for some drug developers. BioWorld detailed several December deals and M&A that boosted end-of-year totals and helped set the stage for follow-on offerings. Underwriters and investors are now watching to see whether that momentum carries into 2026.
What Bay Area Readers Should Know
For local labs, incubators and landlords, the renewed flow of public capital has very real on-the-ground implications. Additional financing for clinical programs often translates into hiring, higher trial spending and renewed demand for lab space. CBRE reported a surge in life-science leasing earlier in 2025, with Peninsula submarkets leading the fourth-quarter rebound, and fresh public raises give companies the cash to expand or retrofit facilities. Still, real expansion depends on how those trials and regulatory milestones play out, not just on splashy financing headlines.
Secondary offerings extend companies’ runway but also dilute existing holders, so investors will be watching execution closely in 2026. Terns’ filings spell out that the proceeds are aimed squarely at development and manufacturing, a common use of funds that can help reduce near-term financing risk if management delivers. Market watchers expect more follow-on deals early next year if M&A and positive data readouts keep sentiment elevated, according to broader capital-markets commentary.
